gamma-aminobutyric acid type A receptor subunit alpha6Genealiases: []
Q-omics provides the consensus-scored GABRA6 profile across patient tissues and cancer cell-line models. GABRA6 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GABRA6 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, GABRA6 RNA expression shows 6,966 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, THCA, and STAD as cancer lineages where GABRA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRA6 survival associations across molecular data types. GABRA6 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRA6 RNA expression–survival associations across cancer types. High GABRA6 expression shows unfavorable associations in COAD, READ, KIRC and DLBC, but favorable associations in UCS and MESO. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for GABRA6 RNA expression.
This table summarizes GABRA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GABRA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRA6 shows lower tumor expression in KIRC, UCEC and COAD and higher tumor expression in THCA and LUSC. The THCA box plot shows higher GABRA6 RNA expression in tumor versus normal tissue (log2 FC = +0.247, t-test p < 0.001).
This table shows molecular features associated with GABRA6 in patient tissues and cancer cell lines. In patient samples, GABRA6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
